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Abstract  
Background: Tasquinimod is a small molecule with immunomodulatory, anti-
angiogenic and anti-metastatic properties that targets the tumor microenvironment.  
Objective: This study aimed to obtain a clinical proof of concept that tasquinimod was 
active and tolerable in patients with advanced solid tumors.  
Patients and Methods: This early stopping design, open-label, proof-of-concept 
clinical trial evaluated the clinical activity of tasquinimod in four independent cohorts 
of patients with advanced hepatocellular (n = 53), ovarian (n = 55), renal cell (n = 38) 
and gastric (n = 21) cancers. Tasquinimod was given orally every day (0.5 mg/day for 
at least 2 weeks, with dose increase to 1 mg/day) until radiological progression 
according to Response Evaluation Criteria in Solid Tumor (RECIST) 1.1 criteria, 
intolerable toxicity or patient withdrawal. The primary efficacy endpoint was 
progression-free survival (PFS) rate according to RECIST 1.1 by central assessment. 
Results: Interim futility analyses at 8 weeks (6 weeks for the gastric cancer cohort) 
found adequate clinical activity of tasquinimod only in the hepatocellular cohort and 
recruitment to the other three cohorts was stopped. PFS rates were 26.9% at 16 
weeks, 7.3% at 24 weeks, 13.2% at 16 weeks and 9.5% at 12 weeks, respectively, in 
hepatocellular, ovarian, renal cell and gastric cancer cohorts. The most common 
treatment-related adverse events were fatigue (48.5%), nausea (34.1%), decreased 
appetite (31.7%), and vomiting (24.6%).  
Conclusions: This study failed to demonstrate clinical activity of tasquinimod in 
heavily pre-treated patients with advanced hepatocellular, ovarian, renal cell and 
gastric cancer. 
Trial registration: NCT01743469 
Key points:  
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 The study involved the application of tasquinimod to patients with the following 
cancers:  hepatocellular, ovarian, renal and gastric. 
 No clinical activity on any of the cancers was demonstrated. 
 The safety profile of tasquinimod across the four cancer patient cohorts was 
consistent with that previously reported in previous studies and no new safety 
concerns were identified. 
Key words: Gastric cancer; Hepatocellular cancer; Ovarian cancer; PFS; Renal cell 
cancer; Tasquinimod 
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1. Introduction 
Tasquinimod is a second-generation oral quinoline-3-carboxamide with multiple 
effects in the tumor microenvironment that inhibits tumor growth and metastasis [1]. A 
key target of tasquinimod is S100A9, a multifunctional immunomodulatory protein 
found in high levels in the microenvironment of several tumor types [1]. S100A9 
interacts with proinflammatory receptors, such as receptor for advanced glycation 
end products (RAGE) and toll-like receptor 4 (TLR4), expressed on myeloid-derived 
suppressor cells (MDSCs), macrophages, endothelial and other cells. Tasquinimod 
binds to S100A9 and inhibits its interaction with RAGE and TLR4 and thereby 
influences the activation and accumulation of MDSCs in the tumor [2, 3, 4] Signals 
produced in the tumor microenvironment appear to stimulate many of the pro-
angiogenic functions of the MDSCs [5]. For example, tumor-infiltrating macrophages 
are stimulated to act as a potent pro-angiogenic force in tumors by exposure to tumor 
hypoxia and/or such tumor cell-derived cytokines as vascular endothelial growth 
factor (VEGF), tumor necrosis factor α and angiopoietin 2. 
 In hepatocellular, ovarian, renal cell and gastric cancers, resistance to 
treatment and disease relapse or progression is common. Angiogenesis is 
significantly involved in the development of these four tumor types, and resistance to 
angiogenesis inhibitors thought to occur by tumor cell adaptation through 
upregulation of pre-existing redundant or evasive mechanisms [6]. Studies have 
shown improved progression-free survival (PFS) in patients with metastatic 
castration-resistant prostate cancer (mCRPC) treated with tasquinimod [7,8]. 
This study was undertaken to obtain clinical proof-of-concept that tasquinimod 
was active and tolerable in patients with advanced hepatocellular (HCC), epithelial 
ovarian (OC), renal cell carcinoma (RCC) or gastric cancers (GC). 
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2. Patients and methods 
This phase II, open-label, proof-of-concept clinical trial (ClinicalTrials.gov identifier 
NCT01743469) was performed at 24 sites in Belgium, Canada, France, Spain and 
the UK (supplementary Table S1, available online). The study was conducted under 
the provisions of the Declaration of Helsinki, and in accordance with the International 
Conference on Harmonization Consolidated Guideline on Good Clinical Practice. The 
protocol and amendments and documents for patients were reviewed and approved 
by an independent ethics committee or institutional review board at each institution 
prior to study start. Written informed consent was provided by all patients 
participating in the study, 
 
2.1 Study participants and treatment 
The study included adult patients with histologically confirmed advanced HCC, OC, 
RCC and GC who had progressed during or after standard therapies. Full inclusion 
and exclusion criteria are provided in supplementary Table S2. All patients were to 
receive tasquinimod at a starting dose of 0.5 mg/day maintained for at least 2 weeks 
and then increased to 1 mg/day when possible. The dose could be maintained or 
reduced in case of Treatment Emergent Adverse Events (TEAEs). 
 
2.2 Study plan and design  
Tasquinimod treatment was given until radiological progression according to 
Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria, the criteria 
validated at the time of the study [9], toxicity or patient withdraw. Full details of study 
visit schedule and clinical assessments are provided in supplementary Tables S3 and 
S4, available online. 
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This study used a two-stage early stopping design (with a futility analysis at 
stage 1) to assess the activity of tasquinimod based on the proportion of patients who 
had neither progressed nor died at pre-defined time points (the PFS rate [10]) in each 
of the four cohorts. The data applied was based on historical data. For each cohort, 
the sample size was calculated based on a one-sided α of ≤ 0.1 and a power of ≥ 
90% together with the constraints that the chance of early stopping given the null 
hypothesis (i.e. tasquinimod showed inadequate clinical activity) was ≥50% and the 
chance of early stopping given the alternative hypothesis was ≤10%. 
The interim futility analysis was performed for each cohort after a pre-defined 
number of patients reached Week 8 (Week 6 for the GC cohort; T1). If the number of 
patients who had not progressed or died at this time was lower than expected so the 
null hypothesis was not rejected, recruitment was stopped; otherwise, recruitment 
continued. The expected PFS rate for an active treatment at T1 (and to pursue the 
recruitment until T2) was 60% for the HCC, 65% for the OC and RCC and 40% for 
the GC cohort. At T2 the expected PFS rates for an active treatment were 40% for 
both the HCC and RCC cohorts at 16 weeks, 55% for the ovarian cancer (OC) cohort 
at 24 weeks and 35% for the gastric cancer (GC) cohort at 12 weeks. The cohort 
patient numbers, analysis timings and expected PFS rates are shown in 
supplementary Table S5. 
 
2.3 Efficacy and safety end points and assessments 
The primary efficacy end point was the proportion of patients who did not progress 
nor died (PFS rate) according to RECIST v1.1 by central assessment at the final 
analysis (T2; see supplementary Table S5 for time points). Secondary efficacy end 
points were PFS duration, response rate, clinical benefit, time to progression (TTP), 
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and overall survival (OS). A patient was considered to have clinical benefit if a 
complete response, a partial response or stable disease was observed for ≥12 or 16 
weeks (according to each cohort) after the first study medication according to 
RECIST criteria. All tumour assessments were appraised by investigators and then 
secondly by a central independent reviewer. Overall response was evaluated using 
the RECIST v1.1 guideline for all cohorts and also by Choi criteria in HCC cohort. 
Safety assessments were performed regularly throughout the study: adverse 
events (AEs), laboratory test values, ECOG performance status, vital signs and 12-
lead electrocardiographic findings were monitored and recorded. AEs and laboratory 
tests were graded using the National Cancer Institute Common Terminology Criteria 
for Adverse Events (NCI-CTCAE) classification version 4.03 (or severity) and coded 
using MedDRA dictionary. 
.  
 
2.4 Statistical analysis 
Efficacy and safety analyses were performed on all patients receiving at least 1 dose 
of tasquinimod. The primary efficacy analysis was the PFS rate (presented with its 
95% confidence interval (CI) calculated using the Clopper-Pearson exact method) 
according to RECIST v1.1 by central assessment at the final analysis (T2). For each 
cohort, the primary analysis was performed at T2 by comparing the PFS rate with the 
pre-specified threshold using a one-sided α of 0.1. For analysis of the time 
dependent parameters as PFS, TTP and OS, the Kaplan-Meier method was used. 
Safety data were analyzed for the Safety Population, separately for each cohort and 
in an overall pooled analysis at T2. The safety analysis was based on treatment 
emergent AEs (TEAEs). For each TEAEs, worst NCI CTCAE (Version 4.03); grade 
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per patient was tabulated by System Organ Class (SOC) and Preferred Term (PT). 
Laboratory values were presented by worst NCI CTCAE grade per patient or 
descriptive statistics. 
 
3 Results 
3.1 Patients and treatment 
From December 2012 to July 2014, 201 patients were screened and 167 patients 
subsequently enrolled in the four separate cohorts. There were 53 patients with HCC, 
55 patients with OC, 38 patients with RCC and 21 patients with GC. Patient 
disposition through the study is shown in Figure 1 and demographic and selected 
clinical characteristics in the four separate cohorts at baseline are shown in 
supplementary Table S6. 
Dose escalation to 1 mg/day was achieved in the majority of patients (62–
77%), while few required a reduction of treatment dose. The median duration of 
treatment ranged from 5.9 weeks in the GC cohort to 9.4 weeks in the HCC cohort 
(supplementary Table S7, available online). Two ovarian and three liver cancer 
patients were treated with tasquinimod for >1 year. 
 
3.2 Efficacy 
For the HCC cohort, the observed PFS rate at T1 was superior to the pre-defined 
rate required to proceed and more patients were enrolled up to the planned total. For 
the OC cohort, recruitment as planned was completed before the T1 futility analysis 
results were available. For the RCC and GC cohorts, the pre-specified PFS rate was 
not achieved and further recruitment was stopped. 
The results presented correspond to the final analysis of all patients enrolled 
and treated at 12 weeks for the gastric cohort, 16 weeks for renal and hepatic cohorts 
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and 24 weeks for the ovarian cohort. Clinical efficacy parameters are shown in Table 
1 for all four cohorts. None of the PFS rates at T2 reached the pre-defined threshold 
for efficacy.  
Kaplan-Meier estimates of PFS and OS in the HCC cohort (n = 53) based on 
central review showed a median (95% CI) of 15.9 (8.0–23.1) and 29.3 (25.0–38.7) 
weeks, respectively (Fig. 2).  
 
3.3 Safety 
All patients experienced at least one TEAE; serious TEAEs occurred in 26–35% of 
patients (Table 2). The majority of TEAEs were considered related to study 
treatment, but most were low grade. Across all patients, the most common TEAEs 
related to treatment were fatigue (48.5%), nausea (34.1%), decreased appetite 
(31.7%), and vomiting (24.6%) (Supplementle Table S8, available online).. 
In all four cohorts, changes in laboratory parameters of grade 3 severity were 
experienced by less than 5% of patients. Increases in liver function tests were 
reported in 14 patients (26.9%) in the HCC cohort and occasionally in the other three 
cohorts. Of particular interest in this study were blood levels of amylase and lipase. 
Abnormal increases of grade 3 or higher severity were noted in 22 patients for lipase 
and five patients for amylase (supplementary Table S9, available online). 
 
 
4 Discussion 
The aim of this study was to evaluate tasquinimod activity in patients with solid 
tumors (liver, ovarian, gastric and renal cancers). At the time of study design, 
tasquinimod had only been evaluated in prostate cancer. The study population 
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selected included patients with advanced cancer types with a high unmet medical 
need reflecting high rates of treatment resistance. In addition, the four advanced 
cancer disease cohorts were selected because the immunomodulatory, anti-
angiogenic and anti-metastatic properties of tasquinimod underpin a mechanism of 
action potentially beneficial in these advanced cancers, especially given the lack of 
standard second- or third-line systemic treatments for these patient populations [1–4, 
8]. 
The four cohorts can be viewed as separate proof-of-concept studies that 
were enrolled through a single protocol. While each cohort of patients was analyzed 
separately for efficacy, the protocol allowed broader capture of information on 
exploratory end points. Notably, the study incorporated an early stopping design with 
futility analyses since, with limited data available regarding the efficacy of 
tasquinimod in other tumor types, exposure to a potentially ineffective drug should be 
kept to a minimum. 
The efficacy analysis revealed that the clinical activity of tasquinimod 
monotherapy was modest even in the HCC cohort, which proceeded to the second 
stage of the statistical design based on the T1 analysis. Tasquinimod, with its 
mechanism of action related to the microenvironment, showed no activity in the 
selected study population with advanced and resistant disease. In developing drugs 
of this type, it might be beneficial to evaluate them in patients with minimal residual 
disease as maintenance therapy after chemotherapy [11].  
In previous phase II and III clinical studies, tasquinimod was administered in 
escalating doses starting with 0.25 mg/day for 2 weeks, followed by 0.5 mg/day for 2 
weeks then, with acceptable tolerability, rising to 1.0 mg/day [6, 7]. In the current 
study, use of 0.5 mg/day as the starting dose allowed dose escalation earlier in the 
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course of treatment and proved to be feasible. The majority of patients then received 
the higher dose of tasquinimod within a flexible dose regimen in which titration based 
on individual tolerability mitigated treatment-related toxicities. The overall safety 
profile of tasquinimod was similar across the four cohorts. As seen in previous 
studies, tasquinimod has a significant rate of toxicities particularly fatigue, 
musculoskeletal and gastrointestinal that can result in the need for dose modification  
[6]. 
Tasquinimod has been evaluated mainly in metastatic castrate resistant 
prostate cancer (mCRPC). In chemonaive mCRPC patients, tasquinimod improved 
radiologic PFS (rPFS) compared with placebo (HR = 0.69, CI 95%: 0.60-0.80) but did 
not extend OS (HR = 1.10, CI 95%: 0.94-1.28). In a subsequent study in mCRPC 
patients previously treated with docetaxel, maintenance tasquinimod therapy 
significantly reduced the risk of rPFS by 40% [12]. In regard to non-solid tumors, 
tasquinimod has recently received orphan drug status in multiple myeloma by the 
Food and Drug Administration. 
In summary, adequate clinical activity of tasquinimod in patients with 
advanced HCC, OC, RCC and GC was not demonstrated in this study. The safety 
profile of tasquinimod across the four cancer patient cohorts was consistent with that 
previously reported in mCRPC and no new safety concerns were identified.  
  
Figure legends 
Fig. 1 Patient disposition. ITT, intent to treat; TEAE, treatment-emergent adverse 
event.  
Fig. 2 Kaplan-Meier estimates of (A) progression-free survival (PFS) based on 
central review and (B) overall survival (OS) for the hepatocellular cancer cohort. 
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Table 1. Summary of tasquinimod efficacy in all treated patients in separate cohorts with hepatocellular, ovarian, renal cell and 
gastric cancers.  
 
Variable Hepatocellular 
(n = 53)a 
Ovarian 
(n = 55) 
Renal cell 
(n = 38) 
Gastric 
(n = 21) 
     
PFS rate at T2b, n (%) [95% CI]     
 RECIST 1.1 criteria  14 (26.4) [15.6, 41.0] 4 (7.3) [2.0, 17.6] 5 (13.2) [4.4, 28.1] 2 (9.5) [1.2, 30.4] 
 Choi criteriac 11 (20.8) [10.8, 34.1] - - - 
P value for PFS rated 0.142 (RECIST 1.1) 
0.50 (Choi) 
1.00 0.80 0.63 
Clinical benefit, n (%) [95% CI]e 14 (26.4) [15.3, 40.3] 11 (20.0) [10.4, 33.0] 6 (15.8) [6.0, 31.3] 0 (0) 
PFS, median (95% CI) weeks 15.9 (8.0, 23.1) 8.0 (7.7, 17.4) 14.9 (7.9, 16.7) 6.0 (5.3, 7.3) 
OS, median (95% CI), range 
weeks 
29.3 (25.0, 38.7), 
1.1–89.4 
NC (30.7, NC),  
2.9–50.0 
32.7 (26.4, 40.9), 
3.4–53.0 
21.6 (13.9, 33.3), 
4.4–49.7 
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Threshold PFS for conclusion at 
T2  
≥ 40% ≥ 55% ≥ 40% ≥ 35% 
aPFS rate based on RECIST 1.1 criteria at T2 for the hepatocellular cohort was reported on 52 patients (as planned in the protocol). 
bTiming of T2 as follows: hepatocellular 16 weeks; ovarian 24 weeks; renal cell 16 weeks; gastric 12 weeks.  
cChoi criteria were used for hepatocellular cancer cohort only. 
dP-values are based on the one-sided exact binomial test (to be compared to 0.1) for observed PFS rates compared with the 
expected PFS rates in the four cohorts: >20% (hepatocellular cancer and renal cancer), >35% (ovarian cancer), and >15% (gastric 
cancer). 
eA patient was considered to have had clinical benefit if a complete response, a partial response or stable disease was observed for 
≥12 weeks after the first study medication according to RECIST criteria. OS, overall survival; NC, not calculated; PFS, progression-
free survival; RECIST 1.1, Response Evaluation Criteria in Solid Tumours version 1.1. 
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Table 2. Overall summary of treatment-emergent adverse events (TEAEs). n (%) values shown. 
TEAE variable Hepatocellular 
(n = 53) 
Ovarian 
(n = 55) 
Renal cell 
(n = 38) 
Gastric 
(n = 21) 
At least one TEAEs 53 (100) 55 (100) 38 (100) 21 (100) 
Maximum intensity     
 Mild (Grade 1) 5 (9.4) 2 (3.6) 5 (13.2) 0 
 Moderate (Grade 2) 11 (20.8) 22 (40.0) 14 (36.8) 12 (57.1) 
 Severe (Grades 3–5) 37 (69.8) 31 (56.4) 19 (50.0) 9 (42.9) 
Causality     
 Not treatment-related 6 (11.3) 6 (10.9) 10 (26.3) 1 (4.8) 
 Treatment-related 47 (88.7) 49 (89.1) 28 (73.7) 20 (95.2) 
Grade of maximum intensity treatment-
related TEAE 
    
 1 10 (18.9) 4 (7.3) 5 (13.2) 2 (9.5) 
 2 20 (37.7) 30 (54.5) 13 (34.2) 15 (71.4) 
 3 17 (32.1) 13 (23.6) 9 (23.7) 3 (14.3) 
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 4 0 2 (3.6) 1 (2.6) 0 
Serious TEAEs     
 Total 14 (26.4) 19 (34.5) 11 (28.9) 7 (33.3) 
 Treatment-related 3 (5.7) 2 (3.6) 4 (10.5) 0 
Consequence/outcome of TEAE     
 Dose reduction 16 (30.2) 12 (21.8) 10 (26.3) 3 (14.3) 
 Dose interruption 30 (56.6) 26 (47.3) 11 (28.9) 12 (57.1) 
 Withdrawal 8 (15.1) 4 (7.3) 8 (21.1) 1 (4.8) 
 Deatha 2 (3.8) 1 (1.8) 1 (2.6) 0 
aDeaths during study treatment period: ovarian cancer: one death due to progressive disease; renal cell cancer: two deaths due to 
disease progression (not reported as a TEAE), one due to TEAE renal failure not related; hepatic cell cancer: one due to renal 
failure (not related) and one due to esophageal varices hemorrhage (not related). 
 
 
 
Enrollment
Allocation
Post-study follow-up
Excluded (n = 34):
• not meeting inclusion criteria 
(n = 29)
• AE (n = 2)
• other reasons (n = 3)
Assessed for eligibility (n = 201)
Enrolled (n = 167)
Hepatocellular cancer
(n = 53)
• Received study treatment 
(n = 53)
• Withdrew from treatment
(n = 50):
– TEAE (n = 10)
– withdrew consent (n = 2)
– disease progression 
(n = 38)
Ovarian cancer (n = 55)
• Received study treatment 
(n = 55)
• Withdrew from treatment 
(n = 52):
– TEAE (n = 5)
– withdrew consent (n = 3)
– disease progression 
(n = 44)
Renal cell cancer (n = 38)
• Received study treatment 
(n = 38)
• Withdrew from treatment 
(n= 38)
– TEAE (n = 8)
– disease progression 
(n = 30)
Gastric cancer (n = 21)
• Received study treatment 
(n = 21)
• Withdrew from treatment 
(n= 21):
– TEAE (n = 1)
– disease progression 
(n = 20)
• Entered follow-up phase 
(n = 49)
• Stopped follow-up (n = 40):
– withdrew consent (n = 1)
– died (n = 38)
– lost to follow-up (n = 1)
• Entered follow-up phase 
(n = 48)
• Stopped follow-up (n = 23):
– died (n = 22)
– lost to follow-up (n = 1)
• Entered follow-up phase 
(n = 37)
• Stopped follow-up (n = 23):
– died (n = 22)
– withdrew consent (n = 1)
• Entered follow-up phase 
(n = 21)
• Stopped follow-up (n = 16):
– died (n = 16)
• ITT and safety population 
(n = 53)
• ITT and safety population
 (n = 55)
• ITT and safety population 
(n = 38)
• ITT and safety population 
(n = 21)
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